Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20163 in Healthy Volunteers

Daewoong Pharmaceutical

Status and phase: Unknown; Phase 1

Conditions: Healthy

Treatments: Drug: Co-administration of DWC20155/DWC20156; Drug: DWC20163

Study type: Interventional

Funder types: Industry

Identifiers

NCT03005223

DW_DWJ1366005

Details and patient eligibility

About

A randomized, open label, crossover study to explore drug-drug interactions between DWC20155 / DWC20156 and DWC20163 in Healthy Volunteers

Enrollment: 52 estimated patients

Sex: Male

Ages: 19 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Accepts healthy volunteers

Exclusion criteria

• Who has allergy to investigational product

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

52 participants in 2 patient groups

Study effect of DWC20163 on DWC20155/DWC20156 PK

Experimental group

Description:

To study effect of DWC20163 on DWC20155/DWC20156 PK

Treatment:

Drug: Co-administration of DWC20155/DWC20156

Drug: DWC20163

Study effect of DWC20155/DWC20156 on DWC20163 PK

Experimental group

Description:

To study effect of DWC20155/DWC20156 on DWC20163 PK

Treatment:

Drug: Co-administration of DWC20155/DWC20156

Drug: DWC20163